ArticleJournal of nanotechnology and nanomaterials2026
Kojic Acid Dipalmitate-Loaded Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Article in Journal of nanotechnology and nanomaterials, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Introduction: Triple-negative breast cancer (TNBC) is responsible for 10-20% of breast cancer cases and is associated with poor prognosis and limited treatment options due to the lack of expression of hormone and HER2 receptors. Kojic acid dipalmitate (KDP) is best known for its skin depigmenting activity; however kojic acid derivatives have shown promising antitumor activity. Such potential remains unexplored for KDP in breast cancer. Methods: KDP-loaded nanoparticles were developed by Results and Discussion: The nanoparticles had a spherical morphology, a hydrodynamic diameter of approximately 240 nm with homogeneous size distribution, a negative zeta potential, and a drug loading of 0.61% ± 0.06 (w/w), in accordance with the drug loading theoretical value, with 100% encapsulation efficiency. FT-IR confirmed KDP incorporation into the nanoparticle. Nanoparticles were stable for 90 days (room temperature and 4°C storage). Cell viability studies with the TNBC cell line (MDA-MB-231) showed a significant, concentration-dependent reduction in cell viability following treatment with KDP-loaded nanoparticles, with an IC Conclusion: These findings highlight the novelty of pH-sensitive KDP-loaded polymeric nanoparticles and support suitability as a nanocarrier platform for poorly soluble drugs like KDP in triple-negative breast cancer research.
Indexed as
Identifiers
42518494PMC13384227What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.